Parsity Group reported that the FDA accepted Alvotech's BLA for AVT80, its proposed interchangeable subcutaneous biosimilar to Entyvio.
Published
Signal category
Customers & Market
Quote
“The FDA accepted Alvotech's BLA for AVT80, its proposed interchangeable subcutaneous biosimilar to Entyvio”
— Dan Nathan|Parsity Group team
Company
Parsity Group
Executive search and leadership consulting firm for the generics, biosimilars and speciality pharmaceutical industries.
- Industry
- Business Consulting and Services
- Location
- London, GB
- Company size
- 8 employees
Parsity Group is a specialised executive search firm that takes a modern and agile approach to attracting leaders for our clients in the generics, biosimilars and speciality pharmaceutical industries. Based on the three pillars of partnership, diversity and agility, we have one aim: to transform pharmaceutical organisations through world class leaders. What sets us apart is our industry specialism, with the knowledge that dynamic, fast paced markets require a different type of leader. Our exclusive focus is on senior and executive hiring for mid-cap and high growth companies solely within generics, biosimilars and speciality pharmaceuticals. This is in the context of Private Equity backed, family/individual owned or public organisations. We offer the following solutions: • Executive search • CEO & Board Services • Professional Search • Interim Solutions • Consulting Services Please get in touch should you wish to hear more.